FDA Approves ATORVASTATIN CALCIUM — Cipla USA Inc.,
The FDA has approved a supplementary ANDA for oral atorvastatin calcium by Cipla USA Inc., allowing the company to expand its generic cholesterol-lowering offerings. This clearance is expected to bolster Cipla's market competitiveness and increase accessibility to this widely prescribed therapeutic.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day